share_log

Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target

Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target

Maxim Group 將 Vistagen Therapeutics 升級爲收購,宣佈目標股價爲30美元
Benzinga ·  2023/08/07 19:09

Maxim Group analyst Jason McCarthy upgrades Vistagen Therapeutics (NASDAQ:VTGN) from Hold to Buy and announces $30 price target.

Maxim集團分析師傑森·麥卡錫將Vistagen Therapeutics(納斯達克股票代碼:VTGN)從持有上調至買入,並宣佈了30美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論